Multiple studies demonstrated that markedly high EBV-IgA reactivity is detectable in NPC cases preceding clinical symptoms supporting the use of EBV-IgA serology for NPC screening in endemic regions [16–20]. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.